The insights and clinical expertise shared in this post and included in the Aspirion Payer Policy Playbook Q3 2026 draw on the expertise of Autumn Resch, LPN, Supervisor, Denials. We are grateful for her dedication to advancing clinical knowledge and her ongoing commitment to supporting our hospital and health system partners.
Medical necessity has long been one of the most complex and resource-intensive denial categories for health systems. But the latest payer updates show that even denials labeled “medical necessity” increasingly hinge on something else.
Updates from UnitedHealthcare, Cigna, Aetna, and CMS all point the same way. Denials increasingly turn on level of care, site of care, preferred therapies, coverage policy, and coding alignment, not clinical severity alone. Health systems that send every “medical necessity” denial to clinical review may be spending valuable nursing time where another fix would work better, and missing revenue they could recover.
The opportunity is significant. Publicly reported data shows a substantial share of appealed prior authorization denials are overturned, yet only a small share are ever appealed.
Here’s what changed:
1. UnitedHealthcare is looking more closely at inpatient stays
UHC’s updated observation and inpatient medical policy for its Commercial and Individual Exchange plans took effect August 1, 2026. It lists conditions the payer considers appropriate for observation, and many of them are among the diagnoses Aspirion appeals most often for health systems. Documenting that the patient was sick isn’t enough on its own. Strong inpatient appeals now address one key question that many appeals don’t cover today.
Aspirion’s Payer Policy Playbook Q3 2026 includes the nine diagnoses we recommend tracking now and the five clinical elements that support a level-of-care appeal.
Get the Playbook by clicking below:
2. CMS-0057-F adds a new consideration for every prior auth appeal
Under the CMS Prior Authorization Final Rule, impacted payers must make prior auth decisions within set timeframes, which vary by payer type, and give a specific reason for every denial. That changes what a complete appeal looks like. Medical necessity is still central. Increasingly, it also matters whether the denial itself was clearly explained and supported.
3. Cigna denials labeled “medical necessity” aren’t always clinical
Cigna ties reimbursement to its coverage criteria, including covered diagnosis and procedure codes. A service can be clinically appropriate and well documented and still be denied if those requirements don’t align. Sending those accounts straight to clinical reviewers uses your most specialized resources on issues they aren’t positioned to resolve.
The right fix starts before the appeal does.
4. Specialty drug denials now focus on where and which therapy
Aetna’s site-of-care requirements for many specialty drug infusions, along with Cigna’s biosimilar-first strategy, mean that many specialty drug denials are not driven by whether treatment was clinically necessary. Instead, denials may hinge on where a medication is administered or whether a preferred therapy was used. Understanding what each denial is actually evaluating helps teams respond with the right information the first time.
The Bigger Opportunity: Payer Intelligence
CMS-0057-F also adds payer reporting requirements, giving health systems new visibility into prior authorization activity and outcomes for impacted plans. The most effective organizations won’t just write better appeals. They’ll use denial data to understand each payer relationship and plan around it.
Get the Payer Policy Playbook
This 11-page guide is built for appeals, coding, CDI, and revenue integrity leaders. Your team can begin putting it to work this week. Classify first. Appeal second. Build payer insight.
Inside:
- The key question every UHC inpatient appeal should answer, the diagnoses to baseline now, and how to build the clinical case
- Prior auth denial details to review and the timeline information to capture before drafting
- A triage framework that routes each denial to the right fix: clinical appeal, coding review, claim correction, or documentation clarification
- Five questions to answer for every payer to turn denial data into revenue strategy
- Five measures RCM leaders should track to make the most of clinical resources
- A 30-day, quarterly, and ongoing action plan so your team knows exactly where to start
Explore the Playbook.
